

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

February 9, 2022

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:40 P.M. (EST) on Wednesday, February 9, 2022, via webinar, accessible to the public through the Plan's website. Quorum was present.

MEMBERS PRESENT:

John Anderson, MD, MPH, Chief Medical Officer, Duke Primary Care

Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians

Phil Seats, RPh, Retired Pharmacist

Sundhar Ramalingam, MD, Oncologist, Duke Cancer Center

Ghassan Al-Sabbagh, MD, Gastroenterologist/ Hepatologist, Gastroenterology and Hepatology Consultants

Laura Rachal, MD, Pediatric Infectious Diseases Specialist, University of North Carolina Hospitals

MEMBERS ABSENT:

David Konanc, MD, Neurologist, Raleigh Neurology Associates

Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center

Sheel Solomon, MD, Dermatologist, Preston Dermatology and Skin Surgery

PLAN & VENDOR STAFF:

Stephanie Craycroft-Andrews, PharmD, BCACP, Sr. Clinical Pharmacist, State Health Plan, Chairperson

Caroline Smart, Sr. Director, Plan Integration, State Health Plan

Dee Jones, Executive Director, State Health Plan

Sonya Dunn, MPA, BSPH, RN, Sr. Pharmacy Benefits Program Manager, State Health Plan

Renée Jarnigan, RPh, Clinical Advisor, CVS Health

Stephanie R. Morrison, PharmD, BCPS, Clinical Advisor, CVS Health

Welcome

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

Conflict of Interest Statement

In compliance with the requirements of Chapter 138A-15(e) of the State Government Ethics Act, the Chairperson read the Plan's Ethics Awareness & Conflict of Interest Reminder to the P&T Committee members and requested that members who have either an actual or perceived conflict of interest identify the conflict and refrain from discussion and voting in those matters as appropriate. No conflicts of interest were noted.

Old Business

The Chairperson asked the P&T Committee members to review the October 27, 2021, P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

The Chairperson asked the P&T Committee members to review the proposed updates to the Charter and By-laws, which were distributed prior to the meeting. Mr. Seats noted a discrepancy between the Charter, which states that committee members must be licensed, and the By-Laws, which specify that committee members must be practicing. As the intent is only that they be required to be licensed, the By-Laws will be edited and redistributed accordingly.

Dr. Anderson opened discussion around the committee's previous vote to remove Eliquis from the formulary effective 1/1/2022. He noted that his health system has observed two instances of thrombotic events in patients whose anticoagulation therapy was interrupted while switching between anticoagulants. Of note, neither of these two patients were State Health Plan members. The committee voted to add Eliquis back to the formulary effective immediately.

Coronavirus Updates

The Chairperson along with Ms. Jarnigan provided informational updates regarding coverage of At-Home Rapid COVID-19 tests and a summary of COVID-19 treatments.

Formulary Updates

The Chairperson introduced CVS Caremark's Clinical Advisors Heather Renée Jarnigan, RPh, & Stephanie Morrison, PharmD, BCPS whom would be presenting CVS Caremark's Quarterly Formulary Updates, effective April 1, 2022. This included additions to the formulary, utilization management criteria, drug removals, and tier movements.

Ms. Jarnigan along with Dr. Morrison and Dr. Craycroft-Andrews identified three new molecular entities that were being removed from CVS's New-to-Market block and would be available as covered products, along with utilization management policies that went along with the new products. The new molecular entities being added to the formulary are as follows: EMPAVELI, LIVMARLI, and RYPLAZIM.

Dr. Morrison then presented other proposed formulary additions, including formulary add-backs and line extensions. The medications being added to the formulary are as follows: GEMTESA, HAEGARDA, ONUREG, EPCLUSA PAK 200-50MG (New GPI), EPCLUSA PAK 150-37.5, BIKTARVY 30 TAB 120-15, XEPI CREAM (New NDCs), TRANDOLAPRIL/VERAPAMIL TAB 2-240 ER, CYCLOPHOSPHAMIDE INJ 2GM/10ML, GVOKE KIT INJ 1MG/0.2, and XARELTO SUS 1MG/ML.

The Committee also approved proposed utilization management including SGM and Specialty QL for EMPAVELI, LIVMARLI, HAEGARDA, ONUREG, and EPCLUSA; SGM for RYPLAZIM; and Specialty QL for BIKTARVY.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug. Ms. Jarnigan then reviewed the following products that will be excluded from the formulary starting on the effective date: EPANED, MYRBETRIQ, DYMISTA, butalbital-acetaminophen capsule, butalbital-acetaminophen tablet 25 mg-325 mg, Vtol LQ, doxycycline hyclate delayed-release tablet (75 mg, 80 mg and 150 mg), prednisolone solution (10 mg/5 ml and 20 mg/5 ml), peg 3350 electrolytes (generics for MoviPrep only), adapalene pad, desonide gel, DesRx, and ciprofloxacin/fluocinolone otic.

All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan's custom formulary. There was no opposition from the Committee members, so these product exclusions were approved as presented.

Dr. Morrison identified all the branded products that will have a change in tier from preferred to non-preferred. They included: SUTENT, BYSTOLIC, and DUREZOL. There was no opposition from the Committee members, so the formulary uptiers were approved as presented.

Adjourn

The Chairperson addressed the Committee by thanking them for their service and informed them that the next meeting would be held on May 11, 2022 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 8:00 P.M. (EST).

Stephanie Craycroft-Andrews

Stephanie Craycroft-Andrews, Chair